Phase II trial of sorafenib in advanced thyroid cancer.

Autor: Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS, Gupta-Abramson, Vandana, Troxel, Andrea B, Nellore, Anoma, Puttaswamy, Kanchan, Redlinger, Maryann, Ransone, Kathy, Mandel, Susan J, Flaherty, Keith T, Loevner, Laurie A

Publikováno v: Journal of Clinical Oncology; 10/10/2008, Vol. 26 Issue 29, p4714-4719, 6p

HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial.

Autor: Li Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Metzger Filho O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Viale G; Division of Pathology, European Institute of Oncology, IRCCS, Milan, Italy.; University of Milan, School of Medicine, Milan, Italy., dell'Orto P; Division of Pathology, European Institute of Oncology, IRCCS, Milan, Italy., Russo L; Division of Pathology, European Institute of Oncology, IRCCS, Milan, Italy., Goyette MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Kamat A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard University, Cambridge, Massachusetts, USA., Yardley DA; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, Tennessee, USA., Gupta Abramson V; Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA., Arteaga CL; University of Texas Southwestern, Simmons Comprehensive Cancer Center, Dallas, Texas, USA., Spring LM; Department of Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA., Chiotti K; Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon, USA., Halsey C; Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon, USA., Waks AG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., King TA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Lester SC; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Bellon JR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Winer EP; Department of Internal Medicine, Yale Cancer Center, New Haven, Connecticut, USA., Spellman PT; Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon, USA., Krop IE; Department of Internal Medicine, Yale Cancer Center, New Haven, Connecticut, USA., Polyak K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2024 Feb 01; Vol. 134 (7). Date of Electronic Publication: 2024 Feb 01.